## **Genomic Psychiatry**

## **OPEN**

## EDITORIAL



# Inaugural Editorial – Introducing *Genomic Psychiatry*: Advancing science from genes to society

© The Author(s), under exclusive licence to Genomic Press 2024

Genomic Psychiatry; https://doi.org/10.61373/gp024d.0004

We are delighted to introduce *Genomic Psychiatry*, a new and groundbreaking medical research journal that aims to revolutionize the field of mental health. Unlike traditional genetics journals, *Genomic Psychiatry* will bridge the gap between genes and the vast array of interconnected disciplines that contribute to our understanding of mental health, advancing science from genes to society.

In recent years, the field of genomics has made significant strides in unraveling the genetic basis of psychiatric disorders. Yet, our editorial conviction is that far more monumental advances will emerge from a nuanced examination of the unbroken spectrum extending from genetics to 'omics sciences, neuroscience, cognitive behaviors, medical imaging, clinical psychiatry, pharmacotherapy, controlled clinical trials, and the farreaching societal implications of mental well-being (1) gene-enviorment interactions, social and environmental exposures.

Recognizing the multifaceted nature of mental health, *Genomic Psy-chiatry* will publish articles that not only delve into genetics and genomics but also embrace a wide range of related topics. We encourage submissions that explore the interplay between genetic markers, environmental factors, social determinants, and resultant mental health profiles (2, 3). From cutting-edge research on the role of epigenetics in psychiatric disorders to studies investigating the social determinants of mental health, we welcome a diversity of perspectives and methodologies.

By embracing a comprehensive approach, *Genomic Psychiatry* will provide a platform for researchers to showcase their work at the intersection of various disciplines (4). This journal will foster collaboration and inspire novel insights, thereby propelling the field forward. We firmly believe that the future of mental health research lies in embracing a multidimensional approach that integrates genetics, genomics, and beyond.

To ensure inclusivity and foster innovation, *Genomic Psychiatry* invites submissions from researchers and clinicians working across the entire spectrum of mental health. We encourage authors to explore the application of genomics and genetics in clinical psychiatry, pharmacological interventions, and treatment trials (5). We are also interested in digital medicine, e-health, and the use of artificial intelligence in computational psychiatry (3). Additionally, we welcome papers that investigate the neurobiological underpinnings of psychiatric disorders, advancements in brain imaging techniques, and behavioral studies that shed light on the complexities of mental health.

As the field of mental health continues to evolve, it is imperative that we create a space that encourages translational science, interdisciplinary collaboration, and knowledge exchange (6). *Genomic Psychiatry* endeavors to be that space, where scientists, clinicians, and researchers from various backgrounds join forces to explore the intricate nature of mental health disorders.

Our editorial board, comprising so far 50 esteemed members, stands as a cornerstone of *Genomic Psychiatry's* strength. These members are not just eminent in their fields but also globally recognized for their contributions. Among them is Nobel Laureate Thomas Südhof, underscoring

Received: 19 January 2024. Accepted: 23 January 2024. Published online: 25 January 2024. the board's prestige. Several members distinguish themselves with affiliations to esteemed institutions: in the US National Academy of Sciences, we have the likes of Huda Akil, Moses Chao, Fred Gage, Jan-Ake Gustafsson, Yasmin Hurd, Robert Malenka, John Rubenstein, and again Thomas Südhof. Within the US National Academy of Medicine, our roster includes Fred Gage, Raquel Gur, Yasmin Hurd, Kenneth Kendler, Robert Malenka, Maria Oquendo, John Rubenstein, Alan Schatzberg, Thomas Südhof, Gustavo Turecki, and Myrna Weissman. The Royal Society honors Jonathan Flint and John Hardy as its Fellows. Additionally, the British monarchy has knighted two of our board members, John Hardy and Michael Owen, in recognition of their extraordinary achievements. This diverse and accomplished group mirrors the unparalleled expertise and global recognition our editorial board enjoys.

We would like to highlight our **Innovators and Ideas** section that spotlights individuals who have made noteworthy contributions to the field. Four of our editorial board members have already contributed to this exciting section as research leaders: Maria Oquendo (neurobiology and clinical approaches to suicidality) (7), Gustavo Turecki (trauma, depression, neuropathology, and genomics) (8), Anthony Grace (brain circuits, schizophrenia, and depression) (9), and Noboru Hiroi (neurobiology of human copy-number variation) (10).

We invite you to embark on this exciting journey with us. Together, let us unravel the mysteries of the human mind, leveraging the power of genomics, genetics, and the wealth of scientific disciplines that converge upon the realm of mental health. Join us in redefining the landscape of psychiatric research and fostering a better understanding of mental health for the benefit of individuals and society as a whole.

Welcome to *Genomic Psychiatry* – where the genetic, the behavioral, the environmental, and the societal merge to develop new paths towards optimal mental health.

### Julio Licinio<sup>1</sup> 🛈

<sup>1</sup>Editor-in-Chief, Genomic Psychiatry, Genomic Press, New York, New York 10036, USA ⊠ e-mail: julio.licinio@genomicpress.com

#### References

- Merikangas KR, Merikangas AK. Harnessing Progress in Psychiatric Genetics to Advance Population Mental Health. Am J Public Health. 2019;109(S3):S171-S175. DOI: 10.2105/AJPH.2019.304948. PMC6595514.
- Reuben A, Manczak EM, Cabrera LY, Alegria M, Bucher ML, Freeman EC, et al. The Interplay of Environmental Exposures and Mental Health: Setting an Agenda. Environ Health Perspect. 2022;130(2):25001. DOI: 10.1289/EHP9889. PMC8848757.
- Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019;25(1):44-56. DOI: 10.1038/s41591-018-0300-7.
- Institute of Medicine (U.S.). Committee on Building Bridges in the Brain Behavioral and Clinical Sciences., Pellmar TC, Eisenberg L. Bridging disciplines in the brain, behavioral, and clinical sciences. Washington, D.C.: National Academy Press; 2000. xiv, 130 p. p.
- 5. Gartlehner G, Wagner G, Matyas N, Titscher V, Greimel J, Lux L, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of



systematic reviews. BMJ Open. 2017;7(6):e014912. DOI: 10.1136/bmjopen-2016-014912. PMC5623437.

- Bornstein SR, Licinio J. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nature medicine. 2011;17(12):1567-1569. DOI: 10.1038/nm.2583.
- Oquendo MA. The translational pathway from the elucidation of the biological contributions to suicide risk to the development of interventions aimed at preventing morbidity and mortality. Genomic Psychiatry. 2024. DOI: 10.61373/gp024k.0001.
- Turecki G. Three fundamental questions How does the brain respond to social and emotional experiences? Why does psychological trauma trigger depressive states? What are the mechanisms of antidepressant responses? Genomic Psychiatry. 2024. DOI: 10.61373/gp024k.0007.
- 9. Grace AA. Elucidating the circuitries that underlie schizophrenia and depression may reveal the impact of stress during development and identify novel treatment targets. Genomic Psychiatry. 2024. DOI: 10.61373/gp024k.0010.
- Hiroi N. Exploring the cellular and developmental origins of neuropsychiatric disorders linked to human copy-number variation. Genomic Psychiatry. 2024. DOI: 10.61373/ gp024k.0013.

Publisher's note: Genomic Press maintains a position of impartiality and neutrality regarding territorial assertions represented in published materials and affiliations of institutional nature. As such, we will use the affiliations provided by the authors, without editing them. Such use simply reflects what the authors submitted to us and it does not indicate that Genomic Press supports any type of territorial assertions.

**Open Access.** This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The license mandates: (1) Attribution: Credit must be given to the original work, with a link to the license and notification of any changes. The acknowledgment should not imply licensor endorsement. (2) NonCommercial: The material cannot be used for commercial purposes. (3) NoDerivatives: Modified versions of the work cannot be distributed. (4) No additional legal or technological restrictions may be applied beyond those stipulated in the license. Public domain materials or those covered by statutory exceptions are exempt from these terms. This license does not cover all potential rights, such as publicity or privacy rights, which may restrict material use. Third-party content in this article falls under the article's Creative Commons license unless otherwise stated. If use exceeds the license scope or statutory regulation, permission must be obtained from the copyright holder. For complete license is provided without warranties.